Expanding the approval to pediatric patients is expected to improve the diagnostic accuracy of echocardiograms. The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A ...

OPTISON (perflutren protein-A microspheres) injectable suspension by GE Healthcare The FDA has approved updated labeling for GE Healthcare's Optison (perflutren protein-type A microspheres injectable ...

The U.S. FDA has approved GE HealthCare’s Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent for use in pediatric patients. The latest approval ...

GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres ...

PRINCETON, NJ ─ November 18, 2013 ─ GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ ...

GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) Upon Approval, GE Healthcare's Oslo ...

GE Healthcare Medical Diagnostics announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in ...

GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands ...

The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ultrasound ...

(RTTNews) - GE HealthCare (GEHC) announced Tuesday the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company's Optison (Perflutren Protein-Type A Microspheres ...